Navigation Links
Biotech industry reaches midpoint in 50-year maturation cycle

If we assume that the biotech industry started in the late 1970s with the first IPOs taking place in 1980 (Amgen and Cetus), then biotech is already an industry more than 25 years old.

An interesting article in Genetic Engineering News (GEN) on March 1 states unequivocally that most industry cycles run about 50 years until they mature. If this ......

Full article >>> s a company developing these products. It was acquired by Eli Lilly in 1986 for more than $400 million.

The success of the founders spawned all kinds of new companies in San Diego. However, it took another 20 years before monoclonal antibodies took off as a technology.
  • Second Decade (late 1980s to late 1990s): A few new discoveries became products using the above methodologies. ......

    Full article >>> icine and life science research but in agriculture, general industry and retail commerce as well.

    During this period, the average life span of humans could reach 125 years. This would mean that tomorrow?s 70-year-old adult will be today?s equivalent of a 35-year-old today.

    So is this science fiction, future shock or the coming reality? A look at the pharmaceutical industry a......

    Full article >>> ed when the program was originally designed.

    In another 10 years, the average age of death in the U.S. may well jump to 95 years or more. This means that social security will be paying out monies to retirees for a period approximating the overall time of work life (30 years) unless the social security retirement age is pushed back further.

    Big Pharma has come mainstream into our ......

    Full article >>> om plastics to herbicides and pesticides to various polymers and fibers.

    Now that they are fully mature industries, what will happen to the pharmaceutical and chemical industries?

    The consolidation of the chemical industry has happened at a much quicker pace than the pharmaceutical industry as many once-innovative products have become commodities. In the pharmaceutical industry, ......

    Full article >>>
    '"/>


  • Source:wistechnology.com By Michael Rosen 04/25/05


    Related biology technology :

    1. Biotech officials praise focus of new venture fund
    2. Biotech executive books a career flight thats closer to home
    3. Gala Biotech among companies sold for $3.3 billion
    4. Biotech with Madison ties raises $21M in capital
    5. Biotech firm uses live heart tissue in drug screens
    6. Biotech talent drew venture-funded firm to Madison
    7. Biotech firm has strokes, Alzheimers in its sights
    8. 42 days until the 2006 Olympics of Biotechnology in Chicago
    9. Biotech crops gaining acceptance, but their full promise has yet to be fulfilled
    10. Biotech leads list of top U.S. companies to work for
    11. Biotech flourishes in 2005 while Big Pharma is on the decline
    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
    (Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
    (Date:6/22/2016)... 2016 Research and Markets has announced the ... to their offering. The ... $29.3 billion in 2013. The market is expected to grow at ... to 2020, increasing from $50.6 billion in 2015 to $96.6 billion ... the forecast period (2015 to 2020) are discussed. As well, new ...
    (Date:6/22/2016)... ... June 21, 2016 , ... New light-based technologies that facilitate a “look inside” ... to enable both compact, wearable devices for point-of-care diagnostics as well as powerful new ... Recent work and visionary future directions are detailed in a new open-access article by ...
    Breaking Biology Technology:
    (Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
    (Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
    (Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
    Breaking Biology News(10 mins):